Patrick G Morris1, Selene Rota2, Karen Cadoo3, Stephen Zamora3, Sujata Patil3, Gabriella D'Andrea3, Theresa Gilewski3, Jacqueline Bromberg3, Chau Dang3, Maura Dickler3, Shanu Modi3, Andrew D Seidman3, Nancy Sklarin3, Larry Norton3, Clifford A Hudis3, Monica N Fornier4. 1. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY; Cancer Clinical Trials and Research Unit, Beaumont Hospital, Dublin, Ireland; Royal College of Surgeons of Ireland, Dublin, Ireland. 2. Department of Medical Oncology, IRCCS Humanitas Clinical and Research Institute, Rozzano, Milan, Italy. 3. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY. 4. Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY. Electronic address: fornierm@mskcc.org.
Abstract
BACKGROUND: Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We showed the feasibility of combining the SRC inhibitor dasatinib with weekly paclitaxel in patients with metastatic breast cancer (MBC) and herein report the subsequent phase II trial. PATIENTS AND METHODS: Patients had received ≤ 2 chemotherapy regimens for measurable, HER2-negative MBC. Patients received paclitaxel and dasatinib (120 mg daily) and were assessed according to Response Evaluation Criteria in Solid Tumors for overall response rate (ORR), the primary end point. Secondary end points included progression-free survival (PFS) and overall survival (OS). A 30% ORR (n = 55) was deemed worthy of further investigation. Exploratory biomarkers included N-telopeptide (NTX) and plasma vascular epidermal growth factor (VEGF) receptor 2 as predictors of clinical benefit. RESULTS: From March 2010 to March 2014, 40 patients, including 2 men enrolled. The study was stopped early because of slow accrual. Overall, 32 patients (80%) had estrogen receptor-positive tumors and 23 (58%) had previously received taxanes. Of the 35 assessable patients, 1 (3%) had complete response and 7 (20%) partial response, resulting in an ORR of 23%. The median PFS and OS was 5.2 (95% confidence interval [CI], 2.9-9.9) and 20.6 (95% CI, 12.9-25.2) months, respectively. As expected, fatigue (75%), neuropathy (65%), and diarrhea (50%) were common side effects, but were generally low-grade. Median baseline NTX was similar in patients who had clinical benefit (8.2 nmol BCE) and no clinical benefit (10.9 nmol BCE). Similarly, median baseline VEGF levels were similar between the 2 groups; 93.0 pg/mL versus 83.0 pg/mL. CONCLUSION: This phase II study of dasatinib and paclitaxel was stopped early because of slow accrual but showed some clinical activity. Further study is not planned.
BACKGROUND: Overexpression and activation of tyrosine kinase Src has been linked to breast carcinogenesis and bone metastases. We showed the feasibility of combining the SRC inhibitor dasatinib with weekly paclitaxel in patients with metastatic breast cancer (MBC) and herein report the subsequent phase II trial. PATIENTS AND METHODS: Patients had received ≤ 2 chemotherapy regimens for measurable, HER2-negative MBC. Patients received paclitaxel and dasatinib (120 mg daily) and were assessed according to Response Evaluation Criteria in Solid Tumors for overall response rate (ORR), the primary end point. Secondary end points included progression-free survival (PFS) and overall survival (OS). A 30% ORR (n = 55) was deemed worthy of further investigation. Exploratory biomarkers included N-telopeptide (NTX) and plasma vascular epidermal growth factor (VEGF) receptor 2 as predictors of clinical benefit. RESULTS: From March 2010 to March 2014, 40 patients, including 2 men enrolled. The study was stopped early because of slow accrual. Overall, 32 patients (80%) had estrogen receptor-positive tumors and 23 (58%) had previously received taxanes. Of the 35 assessable patients, 1 (3%) had complete response and 7 (20%) partial response, resulting in an ORR of 23%. The median PFS and OS was 5.2 (95% confidence interval [CI], 2.9-9.9) and 20.6 (95% CI, 12.9-25.2) months, respectively. As expected, fatigue (75%), neuropathy (65%), and diarrhea (50%) were common side effects, but were generally low-grade. Median baseline NTX was similar in patients who had clinical benefit (8.2 nmol BCE) and no clinical benefit (10.9 nmol BCE). Similarly, median baseline VEGF levels were similar between the 2 groups; 93.0 pg/mL versus 83.0 pg/mL. CONCLUSION: This phase II study of dasatinib and paclitaxel was stopped early because of slow accrual but showed some clinical activity. Further study is not planned.
Authors: Chidananda M Siddappa; Sreeraj G Pillai; Jackie Snider; Patsy Alldredge; Kathyrn Trinkaus; Mark A Watson; Rebecca Aft Journal: Breast Cancer Res Treat Date: 2019-08-20 Impact factor: 4.872
Authors: Petr Lapcik; Anna Pospisilova; Lucia Janacova; Peter Grell; Pavel Fabian; Pavel Bouchal Journal: Cancers (Basel) Date: 2020-09-16 Impact factor: 6.639
Authors: Miguel Angel Galván Morales; Raúl Barrera Rodríguez; Julio Raúl Santiago Cruz; Luis M Teran Journal: Molecules Date: 2020-12-02 Impact factor: 4.411
Authors: John C Dawson; Alison Munro; Kenneth Macleod; Morwenna Muir; Paul Timpson; Robert J Williams; Margaret Frame; Valerie G Brunton; Neil O Carragher Journal: Mol Oncol Date: 2021-12-18 Impact factor: 6.603